Osteoarthritis is characterised by cartilage loss ensuing from the activation of chondrocytes related to a synovial irritation. Activated chondrocytes promote an elevated secretion of matrix proteases and proinflammatory cytokines resulting in cartilage breakdown. Since pure merchandise possess anti-inflammatory properties, we investigated the direct impact of Rubus idaeus extracts (RIE) in chondrocyte metabolism and cartilage loss. The impact of RIE in chondrocyte metabolism was analyzed in murine main chondrocytes and cartilage explants.
We additionally assessed the contribution of RIE in an irritation surroundings by culturing mice main chondrocytes with the supernatant of Uncooked 264.7 macrophage-like cells primed with RIE. In main chondrocytes, RIE diminished chondrocyte hypertrophy (Col10), whereas growing the expression of catabolic genes (Mmp-3, Mmp-13) and decreasing anabolic genes (Col2a1, Acan).
In cartilage explants, Rubus idaeus prevented the lack of proteoglycan (14.84 ± 3.07% lack of proteoglycans with IL1 alone vs. 3.03 ± 1.86% with IL1 and 100 µg/mL of RIE), in addition to the NITEGE neoepitope expression. RIE alone lowered the expression of Il1 and Il6 in macrophages, with out adjustments in Tnf and Cox2 expression. The secretome of macrophages pre-treated with RIE and transferred to chondrocytes decreases the gene and protein expression of Mmp-3 and Cox2. In conclusion, these knowledge counsel that RIE could defend from chondrocyte catabolism and cartilage loss in inflammatory circumstances. Additional evaluations are want earlier than contemplating RIE as a candidate for the therapy for osteoarthritis.
AKAP2 overexpression modulates progress plate chondrocyte capabilities by way of ERK1/2 signaling
In our earlier examine, the mutation c.2645A > C (p. E882A) was discovered within the A-Kinase Anchoring Protein 2 (AKAP2) gene, which performs an vital position in regulating the event of the skeletal system; nonetheless, the precise impact of AKAP2 on chondrocyte proliferation and differentiation and the potential mechanism are nonetheless not clear. Within the current examine, we investigated the impact of AKAP2 in vitro. We efficiently remoted human progress plate chondrocytes (GPCs) from progress plate cartilage tissues and recognized GPCs by aggrecan expression and movement cytometric evaluation.
AKAP2 overexpression considerably promoted GPC proliferation, enhanced GPC differentiation, and promoted extracellular matrix (ECM) synthesis, whereas AKAP2 silencing exerted the alternative results on GPCs. AKAP2 overexpression elevated, whereas AKAP2 silencing decreased, the protein ranges of p-extracellular regulated protein kinases (ERK)1/2.
Extra importantly, the promotive results of AKAP2 overexpression on GPC proliferation, differentiation, and ECM synthesis have been considerably reversed by the ERK1/2 signaling antagonist U0126, suggesting that AKAP2 enhances GPC capabilities by way of ERK1/2 signaling. In conclusion, we reveal AKAP2 overexpression-induced enhancement of GPC capabilities by way of ERK1/2 signaling. Contemplating the important position of GPC capabilities in adolescent idiopathic scoliosis (AIS) pathogenesis, the appliance of AKAP2 concentrating on in AIS therapy must be investigated in future research.

Ameliorative Results of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Mannequin
Arthritis is a typical inflammatory illness that causes ache, stiffness, and joint swelling. Right here, we investigated the ameliorative results of loganin on arthritis in vitro and in vivo. A single bioactive compound was fractionated and remoted from Cornus officinalis (CO) extract to display for anti-arthritic results. A single element, loganin, was recognized as a candidate.
The CO extract and loganin inhibited the expression of things related to cartilage degradation, resembling cyclooxygenase-2 (COX-2), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13), in interukin-1 beta (IL-1β)-induced chondrocyte irritation. As well as, prostaglandin and collagenase ranges have been lowered following therapy of IL-1β-induced chondrocytes with loganin. Within the destabilization of the medial meniscus (DMM)-induced mouse mannequin, loganin administration attenuated cartilage degeneration by inhibiting COX-2, MMP-3, and MMP-13. Transverse micro-CT photos revealed that loganin lowered DMM-induced osteophyte formation. These outcomes point out that loganin has protecting results in DMM-induced mice.
SIRT1 immediately prompts autophagy in human chondrocytes
Osteoarthritis (OA) is the most typical type of arthritis worldwide with no efficient therapy. Ageing is the first threat issue for OA. We sought to research if there’s a distinct and useful convergence of ageing-related mechanisms SIRT1 and autophagy in chondrocytes. Our outcomes present that, ranges of SIRT1 are decreased in human regular aged and OA cartilage in contrast with younger cartilage.
Furthermore, silencing SIRT1 in chondrocytes result in decreased expression of chondrogenic markers however didn’t alter the expression of catabolic proteases. In distinction, activation of SIRT1 elevated autophagy in chondrocytes by the deacetylation of lysine residues on essential autophagy proteins (Beclin1, ATG5, ATG7, LC3). This activation was proven to be mTOR/ULK1 impartial. Our outcomes point out that upkeep of autophagy in chondrocytes by SIRT1 is important for preserving cartilage integrity all through life and due to this fact is a goal for drug intervention to guard in opposition to OA.
Molecular and Mobile Results of Chemical Chaperone-TUDCA on ER-Burdened NHAC-kn Human Articular Chondrocytes Cultured in Normoxic and Hypoxic Circumstances
Osteoarthritis (OA) is taken into account some of the frequent arthritic illnesses characterised by progressive degradation and irregular reworking of articular cartilage. Potential therapeutics for OA purpose at restoring correct chondrocyte functioning and inhibiting apoptosis. Earlier research have demonstrated that tauroursodeoxycholic acid (TUDCA) confirmed anti-inflammatory and anti-apoptotic exercise in lots of fashions of varied illnesses, appearing primarily by way of alleviation of endoplasmic reticulum (ER) stress. Nonetheless, little is thought about cytoprotective results of TUDCA on chondrocyte cells.
The current examine was designed to judge potential results of TUDCA on interleukin-1β (IL-1β) and tunicamycin (TNC)-stimulated NHAC-kn chondrocytes cultured in normoxic and hypoxic circumstances. Our outcomes confirmed that TUDCA alleviated ER stress in TNC-treated chondrocytes, as demonstrated by lowered CHOP expression; nonetheless, it was not efficient sufficient to stop apoptosis of NHAC-kn cells in both normoxia nor hypoxia.
NH2-PEG-COOH,500 |
33-HE005017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-OH,500 |
33-HE006002-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-BIOTIN,500 |
33-HE006041-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Biotin-PEG-COOH,500 |
33-HE041017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
SH-PEG-SH,500 |
33-HO003003-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
AlKyne-PEG-AlKyne,500 |
33-HO007007-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
COOH-PEG-COOH,500 |
33-HO017017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
SC-PEG-SC,500 |
33-HO023023-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MC Cellufine S-500 |
21-200-51 |
JNC America |
5 x 1 ml |
EUR 286.8 |
MC Cellufine S-500 |
21-200-55 |
JNC America |
5 x 5 ml |
EUR 504 |
MC Cellufine C-500 |
19-800-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine C-500 |
19-800-55 |
JNC America |
5 x 5 ml |
EUR 414 |
MC Cellufine Q-500 |
19-907-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine Q-500 |
19-907-55 |
JNC America |
5 x 5 ml |
EUR 414 |
Cellufine A-500 |
675980335 |
JNC America |
10 lt |
Ask for price |
MC Cellufine A-200 |
19-611-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine A-800 |
19-865-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine A-800 |
19-865-55 |
JNC America |
5 x 5 ml |
EUR 414 |
5-Methylcytosine (5-mC) Monoclonal Antibody [33D3] |
A-1014 |
EpiGentek |
-
EUR 721.20
-
EUR 82.50
-
EUR 239.80
-
EUR 456.50
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
MC Cellufine MAX AminoButyl |
21-500-15 |
JNC America |
1 x 5 ml |
EUR 541.2 |
MC Cellufine MAX AminoButyl |
21-500-51 |
JNC America |
5 x 1 ml |
EUR 541.2 |
SH-PEG-NH2,500 |
33-HE003005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MAL-PEG-NH2,500 |
33-HE022005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
NH2-PEG-NH2,500 |
33-HO005005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-N3,500 |
33-HO006006-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MC Cellufine MAX Q-r |
20-500-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Q-r |
20-500-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine Sulfate |
19-845-15 |
JNC America |
1 x 5 ml |
EUR 439.2 |
MC Cellufine Sulfate |
19-845-51 |
JNC America |
5 x 1 ml |
EUR 439.2 |
MC Cellufine Phosphate |
195-15 |
JNC America |
1 x 5 ml |
EUR 516 |
MC Cellufine Phosphate |
195-51 |
JNC America |
5 x 1 ml |
EUR 516 |
Cellufine Q-500 |
675982335 |
JNC America |
10 lt |
Ask for price |
Cellufine C-500 |
675983335 |
JNC America |
10 lt |
Ask for price |
MC Cellufine MAX DEAE |
21-000-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX DEAE |
21-000-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Butyl |
21-100-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Butyl |
21-100-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX GS |
21-300-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX GS |
21-300-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX IB |
21-600-15 |
JNC America |
1 x 5 ml |
EUR 362.4 |
MC Cellufine MAX IB |
21-600-51 |
JNC America |
5 x 1 ml |
EUR 362.4 |
MC Cellufine SPA-HC |
21-900-11 |
JNC America |
1 x 1 ml |
EUR 446.4 |
MC Cellufine SPA-HC |
21-900-15 |
JNC America |
1 x 5 ml |
EUR 663.6 |
MC Cellufine SPA-HC |
21-900-51 |
JNC America |
5 x 1 ml |
EUR 663.6 |
MC Cellufine MAX Phenyl |
20-700-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Phenyl |
20-700-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX CM |
20-900 |
JNC America |
100 ml |
EUR 458.4 |
MC Cellufine MAX CM |
20-900-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX CM |
20-900-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX CM |
20-901 |
JNC America |
500 ml |
EUR 1756.8 |
MC Cellufine MAX CM |
20-902 |
JNC America |
5 lt |
Ask for price |
MC Cellufine MAX CM |
20-903 |
JNC America |
10 lt |
Ask for price |
MC Cellufine Etclean L |
200-15 |
JNC America |
1 x 5 ml |
EUR 427.2 |
MC Cellufine Etclean L |
200-51 |
JNC America |
5 x 1 ml |
EUR 427.2 |
MC Cellufine GH-25 |
19-711-55 |
JNC America |
5 x 5 ml |
EUR 516 |
MC Cellufine Etclean S |
201-15 |
JNC America |
1 x 5 ml |
EUR 427.2 |
MC Cellufine Etclean S |
201-51 |
JNC America |
5 x 1 ml |
EUR 427.2 |
MC Cellufine MAX DexS-Vir |
21-800-15 |
JNC America |
1 x 5 ml |
EUR 362.4 |
MC Cellufine MAX DexS-Vir |
21-800-51 |
JNC America |
5 x 1 ml |
EUR 362.4 |
MC Cellufine MAX S-r |
20-300-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX S-h |
20-400-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX S-h |
20-400-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Q-h |
20-600-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Q-h |
20-600-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Phenyl LS |
20-800-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Phenyl LS |
20-800-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX S-r |
20300-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
Cellufine A-800 |
673980335 |
JNC America |
10 lt |
Ask for price |
Cellufine A-200 |
676-980-327 |
JNC America |
100 ml |
EUR 388.8 |
Cellufine A-200 |
676980335 |
JNC America |
10 lt |
Ask for price |
MBD1 Polyclonal Antibody |
A-1006 |
EpiGentek |
-
EUR 740.34
-
EUR 117.70
-
EUR 306.90
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
5-Hydroxymethylcytosine (5-hmC) Monoclonal Antibody [HMC/4D9] |
A-1018 |
EpiGentek |
-
EUR 702.06
-
EUR 82.50
-
EUR 239.80
-
EUR 443.30
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
PRDM4 Polyclonal Antibody |
A-2004 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM5 Polyclonal Antibody |
A-2005 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM10 Polyclonal Antibody |
A-2010 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM11 Polyclonal Antibody |
A-2011 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM13 Polyclonal Antibody |
A-2013 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM16 Polyclonal Antibody |
A-2016 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM17 Polyclonal Antibody |
A-2017 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
EZH1 Polyclonal Antibody |
A-2018 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
HSF1 Polyclonal Antibody |
A-2401 |
EpiGentek |
-
EUR 905.64
-
EUR 235.40
-
EUR 423.50
-
EUR 574.20
|
- 200 µl
- 50 ul
- 100 ul
- 200 ul
|
PRMT3 Polyclonal Antibody |
A-3003 |
EpiGentek |
-
EUR 740.34
-
Ask for price
-
Ask for price
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SET1 Polyclonal Antibody |
A-3011 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SET07 Polyclonal Antibody |
A-3013 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
LSD1 Polyclonal Antibody |
A-3018 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
HDAC10 Polyclonal Antibody |
A-4010 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PCAF Polyclonal Antibody |
A-4012 |
EpiGentek |
-
EUR 740.34
-
EUR 117.70
-
EUR 306.90
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody |
A-4022 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K14ac (Acetyl H3K14) Polyclonal Antibody |
A-4023 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K18ac (Acetyl H3K18) Polyclonal Antibody |
A-4024 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K23ac (Acetyl H3K23) Polyclonal Antibody |
A-4025 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 383.90
|
|
Histone H3K56ac (Acetyl H3K56) Polyclonal Antibody |
A-4026 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K4me1 (H3K4 Monomethyl) Polyclonal Antibody |
A-4031 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K4me2 (H3K4 Dimethyl) Polyclonal Antibody |
A-4032 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 383.90
|
|
Histone H3K4me3 (H3K4 Trimethyl) Polyclonal Antibody |
A-4033 |
EpiGentek |
-
EUR 555.90
-
EUR 177.10
-
EUR 342.10
-
EUR 479.60
|
|
Histone H3K9me1 (H3K9 Monomethyl) Polyclonal Antibody |
A-4034 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K9me2 (H3K9 Dimethyl) Polyclonal Antibody |
A-4035 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody |
A-4036 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me1 (H3K27 Monomethyl) Polyclonal Antibody |
A-4037 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me2 (H3K27 Dimethyl) Polyclonal Antibody |
A-4038 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody |
A-4039 |
EpiGentek |
-
EUR 555.90
-
EUR 177.10
-
EUR 342.10
-
EUR 479.60
|
|
Histone H3K36me1 (H3K36 Monomethyl) Polyclonal Antibody |
A-4040 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K36me2 (H3K36 Dimethyl) Polyclonal Antibody |
A-4041 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K36me3 (H3K36 Trimethyl) Polyclonal Antibody |
A-4042 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me1 (H3K79 Monomethyl) Polyclonal Antibody |
A-4043 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me2 (H3K79 Dimethyl) Polyclonal Antibody |
A-4044 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me3 (H3K79 Trimethyl) Polyclonal Antibody |
A-4045 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me1 (H4K20 Monomethyl) Polyclonal Antibody |
A-4046 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me2 (H4K20 Dimethyl) Polyclonal Antibody |
A-4047 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me3 (H4K20 Trimethyl) Polyclonal Antibody |
A-4048 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 302.50
-
EUR 470.80
|
|
Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody |
A-4708 |
EpiGentek |
-
EUR 813.42
-
EUR 173.80
-
EUR 299.20
-
EUR 510.40
|
- 100 µl
- 25 ul
- 50 ul
- 100 ul
|
CRISPR Cas9 Monoclonal Antibody [7A9] |
A-9000 |
EpiGentek |
-
EUR 573.30
-
EUR 71.50
-
EUR 200.20
-
EUR 355.30
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
A-9001 |
EpiGentek |
-
EUR 559.38
-
EUR 70.40
-
EUR 192.50
-
EUR 338.80
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
CLIMP-63 Polyclonal Antibody |
A-0701 |
EpiGentek |
-
EUR 754.26
-
EUR 290.40
-
EUR 470.80
|
|
DNMT3A Polyclonal Antibody |
A-1003 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
DNMT3B Polyclonal Antibody |
A-1004 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
DNMT3L Polyclonal Antibody |
A-1005 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
MBD3 Polyclonal Antibody |
A-1008 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
MGMT Polyclonal Antibody |
A-1010 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
MeCP2 Polyclonal Antibody |
A-1012 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
TET1 Polyclonal Antibody |
A-1020 |
EpiGentek |
-
EUR 628.98
-
EUR 221.10
-
EUR 386.10
|
|
DNMT1 Polyclonal Antibody |
A-1700 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
TET2 Polyclonal Antibody |
A-1701 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
MBD2 Polyclonal Antibody |
A-1713 |
EpiGentek |
-
EUR 736.86
-
EUR 281.60
-
EUR 459.80
|
|
PRDM2 Polyclonal Antibody |
A-2002 |
EpiGentek |
-
Ask for price
-
EUR 117.70
-
EUR 284.90
|
|
PRDM3 Polyclonal Antibody |
A-2003 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 470.80
|
|
PRDM6 Polyclonal Antibody |
A-2006 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 470.80
|
|
PRDM12 Polyclonal Antibody |
A-2012 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 383.90
|
|
PRDM14 Polyclonal Antibody |
A-2014 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 470.80
|
|
EZH2 Polyclonal Antibody |
A-2019 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 470.80
|
|
EED Polyclonal Antibody |
A-2020 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
Swi2/SNF2 Polyclonal Antibody |
A-2023 |
EpiGentek |
-
EUR 742.08
-
EUR 303.60
-
EUR 463.10
|
|
SNFa/BRM Polyclonal Antibody |
A-2025 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 383.90
|
|
Ini1 Polyclonal Antibody |
A-2026 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 383.90
|
|
RNA Polymerase II Monoclonal Antibody [CTD4H8] |
A-2032 |
EpiGentek |
-
EUR 754.26
-
EUR 284.90
-
EUR 470.80
|
|
CBX5 Polyclonal Antibody |
A-2701 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
EGLN1 Polyclonal Antibody |
A-2702 |
EpiGentek |
-
EUR 580.26
-
Ask for price
-
Ask for price
|
|
RBBP4 Polyclonal Antibody |
A-2703 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SIN3A Polyclonal Antibody |
A-2704 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
CTBP1 Polyclonal Antibody |
A-2705 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
PADI4 Polyclonal Antibody |
A-2706 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCA5 Polyclonal Antibody |
A-2707 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
IDH1 Polyclonal Antibody |
A-2708 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
CHD4 Polyclonal Antibody |
A-2709 |
EpiGentek |
-
EUR 535.02
-
EUR 322.30
-
EUR 423.50
|
|
CHAF1A Polyclonal Antibody |
A-2710 |
EpiGentek |
-
EUR 535.02
-
EUR 322.30
-
EUR 423.50
|
|
BRD7 Polyclonal Antibody |
A-2712 |
EpiGentek |
-
EUR 535.02
-
EUR 328.90
-
EUR 432.30
|
|
UHRF1 Polyclonal Antibody |
A-2714 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
UHRF2 Polyclonal Antibody |
A-2715 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCE1 Polyclonal Antibody |
A-2716 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
ACTL6A Polyclonal Antibody |
A-2717 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
MPG Polyclonal Antibody |
A-2718 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
HIF1AN Polyclonal Antibody |
A-2719 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
RNF2 Polyclonal Antibody |
A-2720 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
PCGF6 Polyclonal Antibody |
A-2721 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCB1 Polyclonal Antibody |
A-2722 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
ALKBH3 Polyclonal Antibody |
A-2723 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
BBOX1 Polyclonal Antibody |
A-2724 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
BTAF1 Polyclonal Antibody |
A-2725 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
CXXC1 Polyclonal Antibody |
A-2726 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
KDM4B Polyclonal Antibody |
A-2727 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
HELLS Polyclonal Antibody |
A-2728 |
EpiGentek |
-
EUR 742.08
-
EUR 303.60
-
EUR 463.10
|
|
ING3 Polyclonal Antibody |
A-2729 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
ING4 Polyclonal Antibody |
A-2730 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
PHC1 Polyclonal Antibody |
A-2731 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCAD1 Polyclonal Antibody |
A-2732 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
USP16 Polyclonal Antibody |
A-2733 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCC1 Polyclonal Antibody |
A-2734 |
EpiGentek |
-
EUR 742.08
-
EUR 303.60
-
EUR 463.10
|
|
ERCC6L Polyclonal Antibody |
A-2735 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMYD5 Polyclonal Antibody |
A-2736 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
ATF2 Polyclonal Antibody |
A-2738 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
BMI1 Polyclonal Antibody |
A-2739 |
EpiGentek |
-
EUR 869.10
-
Ask for price
-
Ask for price
|
|
CTBP2 Polyclonal Antibody |
A-2740 |
EpiGentek |
-
EUR 869.10
-
EUR 322.30
-
EUR 548.90
|
|
CTCF Polyclonal Antibody |
A-2741 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
MTA2 Polyclonal Antibody |
A-2742 |
EpiGentek |
-
EUR 869.10
-
EUR 322.30
-
EUR 548.90
|
|
PMS1 Polyclonal Antibody |
A-2744 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SFN Polyclonal Antibody |
A-2745 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCA4 Polyclonal Antibody |
A-2746 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
SMARCAL1 Polyclonal Antibody |
A-2747 |
EpiGentek |
-
EUR 869.10
-
Ask for price
-
Ask for price
|
|
SMARCC2 Polyclonal Antibody |
A-2748 |
EpiGentek |
-
EUR 580.26
-
EUR 223.30
-
EUR 353.10
|
|
Nonetheless, co-treatment with TUDCA alleviated inflammatory response induced by IL-1β, as proven by down regulation of Il-1β, Il-6, Il-8 and Cox2, and elevated the expression of antioxidant enzyme Sod2. Moreover, TUDCA enhanced Col IIα expression in IL-1β- and TNC-stimulated cells, however solely in normoxic circumstances. Altogether, these outcomes counsel that though TUDCA could show chondoprotective potential in ER-stressed cells, additional analyses are nonetheless crucial to totally affirm its attainable advice as potential candidate in OA remedy.
Leave a Comment